Assess Terlipressin for Hepatorenal Syndrome

January 2023

Terlipressin (Terlivaz) will be the first FDA-approved med for hepatorenal syndrome with acute kidney injury (HRS-AKI).

HRS-AKI typically occurs in patients with cirrhosis and ascites who develop splanchnic vasodilation. This causes decreased perfusion to the kidneys.

The best treatment is a liver transplant...but many patients don’t qualify for or live long enough to get a transplant.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote